<div class="help-tab">
  <p>
    Each evidence statement is the result of an experiment, trial or study in published literature. It is important to capture the nature of these experiments in the evidence entry. Evidence levels allow for the subject of an evidence item to be presented in a simple, standardized fashion.

  <table class="table table-striped table-condensed table-bordered">
    <colgroup>
      <col width="150">
      <col width="300">
      <col width="920">
    </colgroup>
    <tr>
      <th>Level</th>
      <th>Definition</th>
      <th>Example</th>
    </tr>
    <tr>
      <td class="level levelA"><span class="character">A</span><br/>Validated association</td>
      <td>Proven/consensus association in human medicine.</td>
      <td>"AML with mutated NPM1" is a provisional entity in WHO classification of acute myeloid leukemia (AML). This mutation should be tested for in clinical trials and is recommended for testing in patients with cytogentically normal AML.</td>
    </tr>
    <tr>
      <td class="level levelB"><span class="character">B</span><br/>Clinical evidence</td>
      <td>Clinical trial or other primary patient data supports association.</td>
      <td>ATRA treatment did not effect overall survival in AML patients less than 60 years old with FLT3-ITD mutations.</td>
    </tr>
    <tr>
      <td class="level levelC"><span class="character">C</span><br/>Preclinical evidence</td>
      <td>In vivo or in vitro models support association.</td>
      <td>Experiments showed that AG1296 is effective in triggering apoptosis in cells with the FLT3 internal tandem duplication.</td>
    </tr>
    <tr>
      <td class="level levelD"><span class="character">D</span><br/>Case study</td>
      <td>Individual case reports from clinical journals.</td>
      <td>A single patient with BRAF V600E/V600M bi-allelic mutation responded to the V600E drug dabrafenib.</td>
    </tr>
    <tr>
      <td class="level levelE"><span class="character">E</span><br/>Inferential association</td>
      <td>Indirect evidence.</td>
      <td>Glioma cells harboring IDH1 mutation may be more susceptible to chemotherapy or radiotherapy due to their reduced ability to respond to oxidative stress.</td>
    </tr>
  </table>

</div>
